Immunovia AB (publ)
IMMVFOTCHealthcare● Active
$0.02
+$0.00(+0.00%)
Market Cap$6107816
P/E Ratio—
52W High$0.15
52W Low$0.02
Immunovia AB (publ) (IMMVF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMMVF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.00
Est. -$0.00 · +3.4%
Revenue
$0.00B
Est. $0.00B · -20.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
IMMVF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.00 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.00 | -$0.00 | +3.4% | $0.00B | $0.00B | -20.0% |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$0.00 | -$0.00 | +22.8% | $0.00B | $0.00B | -64.7% |
| — Q2 FY2025 | May 14, 2025 | — | -$0.02 | — | $0.00B | $0.00B | -98.6% |
| — Q1 FY2025 | Feb 25, 2025 | — | $0.00 | — | $0.00B | — | — |
| — Q4 FY2024 | Nov 27, 2024 | — | -$0.11 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 5, 2024 | — | -$0.05 | — | $0.00B | — | — |
| — Q2 FY2024 | Apr 29, 2024 | — | -$0.01 | — | $0.00B | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
+3.4%
Revenue
$0.00B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
+22.8%
Revenue
$0.00B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Feb 25, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Nov 27, 2024
EPS Actual
-$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 5, 2024
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Apr 29, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q4 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +3.4% | $0.02 | $0.02 | +0.00% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +22.8% | $0.02 | $0.02 | +0.00% |
| — Q2 FY2025 | May 14, 2025 | — | $0.05 | $0.05 | +0.00% |
| — Q1 FY2025 | Feb 25, 2025 | — | $0.05 | $0.05 | +0.00% |
| — Q4 FY2024 | Nov 27, 2024 | — | $0.05 | $0.05 | +0.00% |
| — Q3 FY2024 | Aug 5, 2024 | — | $0.05 | $0.05 | +0.00% |
| — Q2 FY2024 | Apr 29, 2024 | — | $0.05 | $0.05 | +0.00% |
| — Q1 FY2024 | Feb 21, 2024 | — | $0.05 | $0.05 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 7, 2026
EPS Beat/Miss
+3.4%
Price Before
$0.02
Price After
$0.02
Q1 FY2026+0.00%
Report Date
Feb 24, 2026
EPS Beat/Miss
+22.8%
Price Before
$0.02
Price After
$0.02
Q2 FY2025+0.00%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q1 FY2025+0.00%
Report Date
Feb 25, 2025
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q4 FY2024+0.00%
Report Date
Nov 27, 2024
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q3 FY2024+0.00%
Report Date
Aug 5, 2024
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q2 FY2024+0.00%
Report Date
Apr 29, 2024
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q1 FY2024+0.00%
Report Date
Feb 21, 2024
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Avg Beat Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMMVF ends December
Immunovia AB (publ) (IMMVF) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.00 — beating the analyst consensus of $-0.00 by +3.4%. IMMVF has beaten EPS estimates for 2 consecutive quarters. The next IMMVF earnings date is expected around September 1, 2026.
Each quarter, investors track IMMVF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMMVF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMMVF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMMVF earnings · 5 questionsImmunovia AB (publ)'s next earnings report is expected around September 1, 2026. IMMVF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMMVF historically reports after market close (AMC).
IMMVF earnings datewhen is IMMVF earningsIMMVF next earnings datewhen does IMMVF report earningsIMMVF earnings calendar
▸ Source: FMP · Immunovia AB (publ) SEC filings · US GAAP · Immunovia AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026